I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

In-stent restenosis (ISR) is an important factor for successful percutaneous coronary intervention (PCI). In the bare-metal stent era, the incidence of ISR was 32--55%. This incidence subsequently decreased but remained 5--15% with the increasing use of drug-eluting stents.\[[@ref1]\] Platelets play an important role in the course of restenosis and neointimal proliferation.\[[@ref2]\] Platelet activation after PCI is persistent and is accompanied by morphological changes.\[[@ref3]\] Larger platelets tend to be more adhesive and more prone to aggregation.\[[@ref4]\] Mean platelet volume (MPV) and platelet distribution width (PDW) are simple platelet parameters that increase during platelet activation. MPV was associated with poor outcome following PCI, including ISR.\[[@ref5][@ref6]\] PDW is regarded as a more specific marker of platelet activation, as it does not increase during simple platelet swelling.\[[@ref7][@ref8]\] The aim of this study was to evaluate the relationship between PDW and ISR in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

EthicaI approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Anzhen Hospital Institutional Ethical Review Board. As a retrospective study and data analysis was performed anonymously, this study was exempt from the informed consent from patients.

Study population {#sec2-2}
----------------

We screened a total of 5232 patients with CAD and T2DM who underwent PCI for the first time from January 2012 to December 2013. A total of 438 patients who underwent coronary angiography again during 3 years of follow-up were included retrospectively. The inclusion criteria were as follows: age ≥18 years, diagnosis of T2DM, and stents implanted were drug eluting stent (DES). The following patients were excluded: acute ST segment elevation myocardial infarction (STEMI), severe heart dysfunction (left ventricle ejection \<30%), end-stage renal dysfunction (evaluated glomerular filtration rate \[eGFR\] \<30%), long-term oral anticoagulation drugs, anemia, and thrombocytopenia below 100,000/μl.

Diagnostic criteria {#sec2-3}
-------------------

Diabetes was diagnosed based on plasma glucose criteria, either fasting plasma glucose, 75-g oral glucose tolerance test, or A1C criteria.\[[@ref9]\] ISR was defined as narrowing of a stent \>50%, including the original treated site and the adjacent vascular segments 5 mm proximal and 5 mm distal to the stent.\[[@ref10]\]

Main measurements {#sec2-4}
-----------------

Blood samples were taken from all patients on admission. The blood samples obtained were kept in standard test tubes containing dipotassium ethylenediaminetetraacetic acid. All samples were analyzed on a Sysmex KX-21N auto-analyzer (Sysmex Corp., Kobe, Japan) within 2 h. All results of coronary angiography were analyzed by two experienced cardiologists and by a third in case of discrepancies.

Statistical analysis {#sec2-5}
--------------------

Continuous data were presented as the mean ± standard deviation (SD), while data not in normal distribution were reported as medians (P~25~, P~75~). Groups of continuous data were compared by Student\'s *t*-test or one-way analysis of variance (ANOVA). If variables were not in normal distribution, the Kruskal-Wallis *H*-test was performed. Categorical variables were presented as percentages and were compared by Chi-square test or Fisher\'s exact test if necessary. The association between PDW and MPV was calculated by the Spearman correlation coefficient. Receiver-operating characteristic (ROC) curve analysis was used to evaluate the best cutoff PDW value for predicting ISR. Logistic regression analysis was used to identify risk factors for ISR. Variables with important clinical meaning and unadjusted *P* \< 0.1 in univariate analysis were entered in the multivariate model. Stepwise selection multivariate logistic regression analyses were performed. The values of the models for predicting ISR were estimated by concordance index (C-index). All probability values were two-sided, and *P* \< 0.05 was considered statistically significant. All analyses were performed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Characteristics of patients {#sec2-6}
---------------------------

Fifty-nine patients with ISR, accounting for 13.5% of all patients, were included. Patients were divided by PDW quartile values (Q1: ≤11.40%, Q2: 11.41--12.80%, Q3: 12.81--14.20%, and Q4: ≥14.21%). The baseline characteristics of patients according to PDW quartiles are displayed in [Table 1](#T1){ref-type="table"}. Seventy percent of patients were male with a mean age of 59.4 years. All patients took aspirin (300 mg loading lose and 100 mg maintenance dose), clopidogrel (300 mg loading dose and 75 mg maintenance dose), and 70 U/kg intravenous heparin perioperatively unless there was a contraindication. In general, there were no significant differences between subgroups in terms of clinical and measurement data aside from the parameters of renal function and platelets values. As this study showed, patients in the higher quartile of PDW value had higher MPV and lower (but normal) platelet counts (PCs). The group of lower quartile of PDW had lower (but normal) eGFR.

###### 

Baseline characteristics according to PDW quartiles

  Parameters                         Total (*n* = 438)      Q1 (≤11.40) (*n* = 98)   Q2 (11.41--12.80) (*n* = 97)   Q3 (12.81--14.20) (*n* = 92)   Q4 (≥14.21) (*n* = 95)   Statistics   *P*^§^
  ---------------------------------- ---------------------- ------------------------ ------------------------------ ------------------------------ ------------------------ ------------ ----------
  Age (years)                        59.4 ± 9.6             60.4 ± 9.6               58.7 ± 9.1                     59 ± 10.2                      59.2 ± 9.8               0.627\*      0.598
  Gender (male)                      272 (71.2)             65 (66.3)                72 (74.2)                      63 (68.5)                      72 (75.8)                2.877^†^     0.411
  BMI (kg/m^2^)                      26.4 ± 3.0             26.4 ± 3.0               26.3 ± 2.7                     26.6 ± 3.2                     26 ± 3.1                 0.540\*      0.655
  Medical history                                                                                                                                                                        
   Hypertension                      264 (69.1)             63 (64.3)                71 (73.2)                      71 (77.2)                      59 (62.1)                6.813^†^     0.078
   Dyslipidemia                      49.5 (189)             47 (48.0)                48 (49.5)                      47 (51.1)                      47 (49.5)                0.186^†^     0.980
   Current smoker                    140 (36.6)             30 (30.6)                40 (41.2)                      32 (34.8)                      38 (40.0)                3.015^†^     0.389
   Family history of CAD             64 (16.8)              8 (8.2)                  21 (21.6)                      18 (19.6)                      17 (17.9)                7.462^†^     0.059
   PAD                               3 (0.8)                1 (1.0)                  0                              1 (1.1)                        1 (1.1)                  1.032^†^     0.794
   Prior stroke                      24 (6.3)               5 (5.1)                  3 (3.1)                        7 (7.6)                        9 (9.5)                  3.826^†^     0.281
   Prior MI                          42 (11.0)              12 (12.2)                8 (8.2)                        8 (8.7)                        14 (14.7)                2.761^†^     0.430
   Prior PCI                         50 (13.1)              14 (14.3)                6 (6.2)                        17 (18.5)                      13 (13.7)                6.566^†^     0.087
   Prior CABG                        5 (1.3)                2 (2.0)                  1 (1.0)                        0                              2 (2.1)                  2.140^†^     0.544
  Concomitant medication                                                                                                                                                                 
   Aspirin                           376 (98.4)             96 (98.0)                95 (97.9)                      92 (100)                       93 (97.9)                1.935^†^     0.586
   Clopidogrel                       379 (99.2)             98 (100.0)               97 (100.0)                     91 (98.9)                      93 (97.9)                3.775^†^     0.287
   β-blocker                         288 (75.4)             73 (74.5)                71 (73.2)                      69 (75.0)                      75 (78.9)                0.950^†^     0.813
   ACEI or ARB                       166 (49.0)             42 (42.8)                51 (52.6)                      49 (53.2)                      46 (48.4)                0.102^†^     0.992
   Statin                            360 (94.2)             93 (94.9)                94 (96.9)                      88 (95.7)                      85 (89.5)                3.435^†^     0.129
   CCB                               120 (31.4)             31 (31.6)                31 (32.0)                      33 (35.9)                      25 (26.3)                5.664^†^     0.570
   Hypoglycemic drugs                237 (60.0)             52 (53.1)                61 (62.9)                      60 (65.2)                      64 (67.4)                4.924^†^     0.177
   Insulin                           82 (21.5)              23 (23.5)                20 (20.6)                      16 (17.4)                      23 (24.2)                1.605^†^     0.658
  Clinical presentation                                                                                                                                                                  
   Stable angina                     70 (18.3)              22 (22.4)                19 (19.6)                      14 (15.2)                      15 (15.8)                2.219^†^     0.528
   Unstable angina                   310 (81.2)             75 (76.5)                78 (80.4)                      77 (83.7)                      80 (81.2)                2.373^†^     0.499
  Examination finding on admission                                                                                                                                                       
   LVEF (%)                          62 (58, 68)            60 (58, 66)              61 (58, 66)                    64 (58, 69)                    64 (59, 69)              3.517^‡^     0.319
   TG (mmol/L)                       1.7 (1.2, 2.4)         1.8 (1.2, 2.4)           1.7 (1.3, 2.4)                 1.6 (1.1, 2.3)                 1.8 (1.3, 2.8)           2.305^‡^     0.512
   TC (mmol/L)                       4.4 ± 1.1              4.4 ± 1.0                4.5 ± 1.1                      4.3 ± 1.1                      4.5 ± 1.1                0.853\*      0.466
   LDL-C (mmol/L)                    2.8 ± 0.9              2.7 ± 0.9                2.8 ± 0.8                      2.7 ± 0.9                      2.8 ± 1.0                0.521\*      0.668
   HDL (mmol/L)                      1.0 (0.8, 1.2)         1.0 (0.8, 1.2)           1.0 (0.9, 1.2)                 1.0 (0.9, 1.2)                 0.9 (0.8, 1.1)           5.546^‡^     0.136
   VLDL (mmol/L)                     0.6 (0.3, 0.8)         0.5 (0.4, 0.8)           0.6 (0.4, 0.8)                 0.5 (0.3, 0.7)                 0.6 (0.3, 0.8)           3.489^‡^     0.322
   HbA1C (mmol/L)                    7.0 (6.4, 7.9)         7.0 (6.4, 7.8)           7.1 (6.5, 7.9)                 7.0 (6.2, 7.8)                 7.0 (6.4, 8.0)           2.846^‡^     0.416
   Creatine (µmol/L)                 76.6 ± 17.5            80.1 ± 15.3              79.1 ± 20.5                    75.5 ± 17.4                    73.8 ± 15.9              2.773\*      0.041
   eGFR (ml·min^-1^·1.73 m^-2^)      97.6 (82.2, 115.5)     89.8 (76.4, 108.70       98.4 (79.5, 114.1)             98.6 (85.5, 115.6)             103.0 (88.4, 123.7)      12.735^‡^    0.005
   Uric acid (µmol/L)                338.8 (283.5, 115.5)   346.8 (285.9, 415.5)     362.8 (298.8, 427.7)           341.1 (290.0, 406.7)           335.4 (287.2, 411.3)     3.797^‡^     0.284
   CRP (mg/L)                        1.7 (0.8, 3.5)         1.3 (0.8, 3.0)           1.6 (0.6, 3.7)                 2.0 (0.7, 4.0)                 1.8 (0.9, 3.3)           2.180^‡^     0.536
   CK-MB (U/L)                       10 (1, 13)             9.0 (0.5, 12.8)          9.0 (1.1, 13.0)                10.5 (1.2, 14.0)               9.0 (0.9, 13)            2.601^‡^     0.457
   HGB on admission (g/L)            140.2 ± 18.8           138.1 ± 15.3             144.6 ± 15.3                   141.7 ± 19.5                   138.6 ± 23.5             1.807\*      0.146
   Platelet count (×10^6^/L)         186 (162, 234)         219 (174, 261)           205 (177, 250)                 203 (167, 237)                 163 (133, 202)           44.596^‡^    \<0.0001
   PCT (%)                           20.0 (16.8, 24.0)      21.0 (16.0, 25.8)        21.0 (18.0, 25.0)              21.0 (18.0, 25.0)              18.0 (10.5, 21.5)        29.345\*     \<0.0001
   MPV (fl)                          10.5 (9.8, 11.1)       9.8 (9.3, 10.0)          10.5 (10.2, 10.7)              11.1 (10.9, 11.3)              11.7 (8.4, 12.1)         133.662^‡^   \<0.0001

Data are shown as mean ± SD, median (P~25~, P~75~) or *n* (%). \*Analysis of variance, *F* values; ^†^Chi-square test, *χ*^2^ values; ^‡^Kruskal-Wallis *H*-test, *H* values; ^§^*P*: Q1 versus Q2 versus Q3 versus Q4. BMI: Body mass index; CAD: Coronary artery disease; PAD: Peripheral vascular disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blocker; CCB: Calcium channel blockers; LVEF: Left ventricular ejection fraction; TG: Triglyceride; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL: High-density lipoprotein; VLDL: Very low-density lipoprotein; eGFR: Evaluated glomerular filtration rate; CRP: C-reactive protein; CK-MB: Creatine kinase-MB; HGB: Hemoglobin; PCT: Plateletcrit; MPV: Mean platelet volume; SD: Standard deviation; HbA1C: Glycated hemoglobin; PDW: Platelet distribution width.

Procedural characteristics {#sec2-7}
--------------------------

Procedural characteristics of patients as divided according to PDW values are displayed in [Table 2](#T2){ref-type="table"}. A transradial approach using 6 or 7 Fr guiding catheters and second-generation DESs was used. The particular type of stent was decided by the operator. No significant differences among quartiles were shown with respect to procedural data. ISR was significantly more frequent in patients with higher PDW quartiles compared with lower quartiles. Incidence of ISR of group Q1--Q4 was 7.1%, 9.3%, 17.4%, and 28.4%, respectively (χ^2^ = 20.512, *P* \< 0.0001). As shown in [Figure 1](#F1){ref-type="fig"}, we observed that PDW had a strong relationship with MPV (*r* = 0.647, 95% confidence interval \[*CI*\]: 0.535--0.750, *P* \< 0.0001).

###### 

Procedural characteristics according to PDW quartiles

  Parameters                   Total (*n* = 438)   Q1 (≤11.40) (*n* = 98)   Q2 (11.41--12.80) (*n* = 97)   Q3 (12.81--14.20) (*n* = 92)   Q4 (≥14.21) (*n* = 95)   Statistics   *P*^‡^
  ---------------------------- ------------------- ------------------------ ------------------------------ ------------------------------ ------------------------ ------------ ----------
  SYNTAX score                 10 (7, 16)          10 (7, 15)               10 (7, 15)                     11 (7, 16)                     11 (7, 17)               0.783\*      0.853
  Number of lesion vessels     2 (1, 3)            2 (1, 3)                 2 (1, 3)                       2 (1, 3)                       2 (1, 2)                 2.780\*      0.427
  One-vessel disease           128 (33.5)          37 (37.8)                34 (35.1)                      25 (27.2)                      32 (33.7)                2.555^†^     0.465
  Two-vessel disease           142 (37.2)          34 (34.7)                30 (30.9)                      37 (40.2)                      41 (43.2)                3.700^†^     0.296
  Multivessel disease (≥2)     112 (66.5)          27 (62.3)                33 (64.9)                      30 (72.8)                      22 (66.4)                3.403^†^     0.334
  LM                           9 (2.4)             2 (2.0)                  2 (2.1)                        2 (2.2)                        3 (3.2)                  0.358^†^     0.949
  LAD                          209 (54.7)          57 (58.2)                55 (56.7)                      52 (56.5)                      45 (47.4)                5.017^†^     0.542
  LCX                          128 (33.5)          27 (27.6)                28 (28.9)                      32 (34.8)                      41 (43.2)                9.355^†^     0.155
  RCA                          132 (34.6)          37 (37.8)                31 (32.0)                      29 (31.5)                      35 (36.8)                4.337^†^     0.631
  CTO                          14 (3.7)            3 (3.1)                  4 (4.1)                        3 (3.3)                        4 (4.2)                  0.145^†^     0.986
  Bifurcation                  3 (0.8)             0                        0                              2 (2.2)                        1 (1.1)                  3.907^†^     0.272
  Number of stents             2 (1, 3)            2 (1, 3)                 2 (1, 3)                       2 (1, 2)                       1 (1, 3)                 0.376\*      0.945
  Minimum stent diameter, mm   2.75 (2.5, 3.5)     2.9 (2.5, 3.5)           3.0 (2.5, 3.5)                 3.0 (2.5, 3.5)                 3.0 (2.5, 3.5)           0.733\*      0.865
  Mean length of stent, mm     20.5 (17.5, 26.0)   20.8 (18.0, 25.7)        19.2 (16.4, 25.6)              23.0 (16.5, 28.0)              20.0 (18, 24.0)          2.576\*      0.462
  ISR                          59 (15.4)           7 (7.1)                  9 (9.3)                        16 (17.4)                      27 (28.4)                20.512^†^    \<0.0001

Data are shown as *n* (%) or median (P~25~, P~75~). \*Kruskal-Wallis *H*-test, *H* values; ^†^Chi-square test, *χ*^2^ values; ^‡^*P*: Q1 versus Q2 versus Q3 versus Q4. SYNTAX score: Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score; LM: Left main artery; LAD: Left anterior descending coronary artery; LCX: Left anterior descending coronary artery; RCA: Right coronary artery; CTO: Chronic total occlusion; PDW: Platelet distribution width; ISR: In-stent restenosis.

![Correlation between mean platelet volume and platelet distribution width. *r* = 0.647, 95% *CI*: 0.535--0.750, *P* \< 0.0001. MPV: Mean platelet volume; PDW: Platelet distribution width; *CI*: Confidence interval.](CMJ-131-757-g001){#F1}

Relationship between platelet distribution width and in-stent restenosis {#sec2-8}
------------------------------------------------------------------------

As shown in [Figure 2](#F2){ref-type="fig"}, ROC curves showed that the PDW cutoff value for predicting ISR rate was 13.65 fl with sensitivity of 59.3% and specificity of 72.4% (area under the curve \[AUC\] = 0.701; 95% *CI*: 0.625--0.777; *P* \< 0.001). We defined high PDW as more than 13.65 fl.

![Receiver-operating characteristic curve for platelet distribution width for predicting in-stent restenosis. AUC = 0.701, 95% *CI*: 0.625--0.777, *P* \< 0.0001. AUC: Area under curve; *CI*: Confidence interval.](CMJ-131-757-g002){#F2}

As shown in [Table 3](#T3){ref-type="table"}, univariate logistic regression analysis demonstrated that variables, such as uric acid, MPV, SYNTAX score, and number of stents, were statistically significant risk factors for ISR in accordance with previous study.\[[@ref11]\] To describe the relationship between PDW and ISR, we used three models of PDW, that is, PDW, high PDW, defined as more than 13.65 fl, and PDW quartiles, as variables. As shown in [Table 4](#T4){ref-type="table"}, the unadjusted odds ratio (*OR*) was 1.335 (95% *CI*: 1.199--1.488, *P* \< 0.0001) for PDW to predict ISR, 3.834 (95% *CI*: 2.160--6.807, *P* \< 0.0001) for high PDW to predict ISR. Compared with Q1, the unadjusted *OR* was 1.33 (95% *CI*: 0.475--3.725, *P* =0.588) for Q2 to predict ISR, 2.737 (95% *CI*: 1.070--6.999, *P* = 0.036) for Q3 to predict ISR, 5.162 (95% *CI*: 2.122--12.553, *P* \< 0.0001) for Q4 to predict ISR, respectively. On multivariate analysis, variables such as age, sex, body mass index, hypertension, dyslipidemia, prior myocardial infarction, prior PCI, prior stoke, current smoking, aspirin use, clopidogrel use, statin use, eGFR, glycated hemoglobin, C-reactive protein, PC, plateletcrit, MPV on admission, SYNTAX score, mean stent length, and number of stents were entered into stepwise logistic regression models. Multivariate analysis revealed that the risk of ISR increased approximately 30% when PDW increased one unit (*OR*: 1.289, 95% *CI*: 1.110--1.498, *P* = 0.001). Patients with higher PDW, defined as more than 13.65 fl, had a 4-fold higher risk of ISR compared with lower PDW (*OR*: 4.241, 95% *CI*: 1.879--9.572, *P* = 0.001). Furthermore, when patients were divided by PDW quartiles, PDW had a great value of predicting ISR (Q2: *OR* = 0.762, 95% *CI*: 0.189--3.062, *P* = 0.762; Q3: *OR* = 2.782, 95% *CI*: 0.865--8.954, *P* = 0.086; and Q4: *OR* = 3.849, 95% *CI*:1.225--12.097, *P* =0.021, respectively; *P* for trend \<0.0001). To evaluate the prognostic power of multivariate model as shown in [Table 3](#T3){ref-type="table"}, the concordance (C) index was calculated (C-index for PDW: 0.731, 95% *CI*: 0.642--0.819, *P* \< 0.0001; C-index for high PDW: 0.692, 95% *CI*: 0.610--0.773, *P* \< 0.0001; and C-index for PDW quartiles: 0.690, 95% *CI*: 0.608--0.773, *P* \< 0.0001, respectively).

###### 

Univariate logistic regression analysis of predictors for ISR

  Variable              *OR* (95% *CI*)         Wald *χ*^2^   *P*
  --------------------- ----------------------- ------------- -------
  Age                   0.990 (0.962--1.018)    0.521         0.471
  Current smoking       0.628 (0.341--1.157)    2.229         0.135
  Hypertension          0.797 (0.445--1.428)    0.580         0.447
  Dyslipidemia          0.645 (0.375--1.141)    2.233         0.135
  Prior MI              0.933 (0.378--2.305)    0.022         0.881
  Prior PCI             1.477 (0.700--3.117)    1.049         0.306
  Aspirin               0.933 (0.110--7.890)    0.004         0.949
  Clopidogrel           0.151 (0.021--1.095)    3.498         0.061
  Statin                0.930 (0.311--2.781)    0.017         0.896
  LDL-C                 0.861 (0.629--1.178)    0.872         0.350
  Creatine              0.998 (0.982--1.014)    0.077         0.782
  eGFR                  1.000 (0.998--1.001)    0.077         0.782
  HbA1C                 1.057 (0.858--1.303)    0.270         0.604
  Uric acid             0.997 (0.995--1.000)    4.359         0.037
  CRP                   0.991 (0.930--1.058)    0.068         0.795
  Platelet              0.998 (0.992--1.003)    0.767         0.381
  PCT                   0.903 (0.002--39.254)   0.001         0.974
  MPV                   1.267 (1.037--1.548)    5.373         0.020
  Syntax score          1.043 (1.004--1.083)    4.672         0.031
  Mean stent length     1.011 (0.981--1.043)    0.536         0.464
  Mean stent diameter   0.605 (0.300--2.128)    0.238         0.686
  Number of stents      1.411 (1.152--1.729)    11.047        0.001

MI: Myocardial infarction; PCI: Percutaneous coronary intervention; LDL-C: Low-density lipoprotein cholesterol; eGFR: Evaluated glomerular filtration rate; CRP: C-reactive protein; PCT: Plateletcrit; MPV: Mean platelet volume; SYNTAX score: Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score; *CI*: Confidence interval; HbA1C: Glycated hemoglobin; *OR*: Odds ratio; ISR: In-stent restenosis.

###### 

Prognostic significance of PDW of predicting ISR

  Model               *OR* (95% *CI*)         Wald *χ*^2^   *P*        Adjusted *OR* (95% *CI*)   Wald *χ*^2^   *P*
  ------------------- ----------------------- ------------- ---------- -------------------------- ------------- -------
  Total               1.335 (1.199--1.488)    27.615        \<0.0001   1.289 (1.110--1.498)       11.002        0.001
  High PDW            3.834 (2.160--6.807)    21.065        \<0.0001   4.241 (1.879--9.572)       20.516        0.001
  Q1 (≤11.40)\*       1.00 (reference)                                 1.00 (reference)                         
  Q2 (11.41--12.80)   1.33 (0.475--3.725)     0.294         0.588      0.762 (0.189--3.062)       0.147         0.762
  Q3 (12.81--14.20)   2.737 (1.070--6.999)    4.417         0.036      2.782 (0.865--8.954)       2.945         0.086
  Q4 (≥14.21)         5.162 (2.122--12.553)   13.103        \<0.0001   3.849 (1.225--12.097)      19.231        0.021

High PDW defined as more than 13.65 fl calculated by this study. \**P* for trend \<0.0001; C-index for total: 0.731, 95% *CI*: 0.642--0.819, *P*\<0.0001; C-index for high PDW: 0.692, 95% *CI*: 0.610--0.773, *P*\<0.0001; C-index for PDW quartiles: 0.690, 95% *CI*: 0.608--0.773, *P*\<0.0001. PDW: Platelet distribution width; *CI*: Confidence interval; *OR*: Odds ratio; ISR: In-stent restenosis.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

We observed that PDW is an independent risk factor for ISR in patients with CAD and T2DM. Another study showed that ISR was an independent risk factor for mortality.\[[@ref12]\]

Vascular endothelium suffers mechanical damage post-PCI, which induces such overreactions as plaque rupture, and platelet and leukocyte activation. This effect can induce the release of inflammatory mediators and chemical chemokines and can increase the risk of ISR and cardiovascular events post-PCI.\[[@ref13]\] Platelet activation is caused by the release of inflammatory mediators from α particles, which induces smooth muscle cell proliferation and spread, as well as vascular spasm. Fibrin and platelets play important roles in the process of ISR post-PCI.\[[@ref14]\] Fuster *et al*.\[[@ref15]\] demonstrated mural thrombi in vascular walls postoperatively, promoting the occurrence of ISR.

During activation, platelets reorganize their cytoskeleton and change shape through a process of metamorphosis.\[[@ref16]\] *In vitro*, larger platelets are more rapidly aggregated compared with small platelets induced by ADP, collagen, and adrenaline. These platelets produce more prothrombotic and vasoactive factors (e.g., thromboxane A2, serotonin, ATP, and dense granules). Large platelets express higher levels of adhesion molecules (e.g., P-selectin, GpIIb/IIIa).\[[@ref17]\] The major factor influencing platelet-dependent hemostatic function in healthy people is platelet mass (PM), which is the product of PC × platelet volume (MPV). The two parameters had an inverse curvilinear relationship, and PM remained stable.\[[@ref18]\] However, the relationship could be disrupted in disease states.

MPV and PDW are well-known morphological parameters in platelets. It has been shown that there was a strong relationship between MPV and prognosis post-PCI with a higher 6-month mortality rate in patients with higher MPV (12.1% vs. 5.1%, *P* = 0.0125).\[[@ref5]\]

Recent studies observed that PDW may be considered to be a more specific marker than MPV, enabling early and easy identification of patients with poor prognosis. Studies suggested that PDW had an association with the severity of coronary disease. Vatankulu *et al*.\[[@ref19]\] showed that the cutoff PDW value for identifying patients with CTO was 15.7% with a sensitivity of 64.0% and a specificity of 66% (AUC = 0.64, 95%*CI*:0.54--0.75). Akin *et al*.\[[@ref20]\] showed that PDW was positively associated with SYNTAX score (*r* = 0.209, *P* \< 0.001) in patients with STEMI who underwent primary PCI, and PDW was an independent risk factor for high SYNTAX score (*OR* = 1.229, 95% *CI*:1.072--1409, *P* = 0.003).

In addition, it was demonstrated that PDW had a strong association with major adverse cardiac event in patients undergoing PCI. Ulucan *et al*.\[[@ref21]\] showed that preprocedural PDW was an independent predictor of both in-hospital and long-term adverse outcomes in patients with ACS (*OR* = 1.081, 95% *CI*: 1.003--1.165, *P* = 0.0001). Cetin *et al*.\[[@ref22]\] observed that PDW was significantly higher in the thrombolysis failure group than that in the success group (17.7 ± 1.0 vs. 16.4 ± 2.1 fl, *P* \< 0.001) in patients with STEMI. PDW was an independent predictor of thrombolysis failure.

According to recent studies, monitoring and personalizing antiplatelet therapy failed to improve the prognosis of patients with PCI. This failure could be explained by neither the risk level of the population nor the type of P2Y12 antagonist.\[[@ref23][@ref24]\] Given the complexity of the pathophysiology of thrombosis, it might be wise to integrate platelet function tests, platelet morphological examination, and *MDR1* or *CYP2C19\*2* genetic tests to guide antithrombotic therapy to eliminate the risk of ISR. Of course, we need further larger studies to demonstrate the relationship between PDW and ISR and the benefits of PDW-guiding antithrombotic therapy.

There were several limitations in this study. First, this study was a retrospective study with single-center design. Second, the study might underestimate the incidence rate because only patients undergoing second coronary angiography were included. Third, we did not consider other platelet volume indices, such as platelet large cell ratio, which has been shown to be linked with platelet functional and perioperative anticoagulant therapy, possibly affecting the outcome.

In conclusion, PDW is an independent predictor of ISR in patients with CAD and PCI.
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